Logo

BOLD

Boundless Bio, Inc.

BOLD

Boundless Bio, Inc. • NASDAQ
$1.17 ▲ 5.41% (+0.06)
Market Cap $26.19 M
52w High $3.54
52w Low $1.00
Dividend Yield 0%
P/E -0.44
Volume 89.78K
Outstanding Shares 22.39M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $14.838M ▼ $-13.879M ▲ 0% $-0.62 ▲ $-13.569M ▲
Q2-2025 $0 $16.744M ▼ $-15.675M ▲ 0% $-0.7 ▲ $-15.358M ▲
Q1-2025 $0 $17.341M ▼ $-15.758M ▲ 0% $-0.71 ▲ $-17.024M ▲
Q4-2024 $0 $18.278M ▼ $-16.448M ▲ 0% $-0.84 ▼ $-17.982M ▲
Q3-2024 $0 $18.715M $-16.509M 0% $-0.74 $-18.453M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $117.57M ▼ $168.721M ▼ $58.552M ▲ $110.169M ▼
Q2-2025 $127.148M ▼ $179.453M ▼ $56.762M ▲ $122.691M ▼
Q1-2025 $138.253M ▼ $191.242M ▼ $54.65M ▼ $136.592M ▼
Q4-2024 $152.114M ▼ $206.409M ▲ $55.767M ▲ $150.642M ▼
Q3-2024 $167.135M $175.093M $10.01M $165.083M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-13.879M ▲ $-10.195M ▲ $10.478M ▼ $0 ▼ $283K ▲ $-10.21M ▲
Q2-2025 $-15.675M ▲ $-11.829M ▲ $11.292M ▲ $117K ▲ $-420K ▲ $-11.877M ▲
Q1-2025 $-15.758M ▲ $-14.53M ▲ $3.06M ▲ $0 ▼ $-11.47M ▲ $-14.589M ▲
Q4-2024 $-16.448M ▲ $-15.563M ▼ $1.823M ▼ $113K ▲ $-13.627M ▼ $-16.029M ▼
Q3-2024 $-16.509M $-13.266M $22.13M $-13K $8.851M $-13.749M

Five-Year Company Overview

Income Statement

Income Statement Boundless Bio is still a pure research-stage biotech company, so it has essentially no product revenue yet. The income statement is entirely driven by research and operating expenses, which lead to recurring losses each year. Those losses have been gradually widening as the company invests more in clinical development and its platform. This pattern is typical for early-stage biotech: spending first, potential revenue much later, and only if the science and trials succeed. Until there is clear clinical validation and potential partnerships or product approvals, the income statement will likely remain loss-making.

Balance Sheet

Balance Sheet The balance sheet shows a young company with modest total assets but a growing cash and asset base over time, likely helped by fundraising. Equity has moved from negative to positive territory, which suggests recent capital inflows and a cleaner capital structure. Debt is present but not overwhelming, and the company still relies far more on equity funding than borrowing. The main strength is the improved financial cushion; the main risk is that the asset base is mostly cash and intangibles tied to R&D rather than established products or hard assets.

Cash Flow

Cash Flow Cash flows tell the story of a biotech that is firmly in investment mode. Operating cash flow is consistently negative, reflecting ongoing research, clinical trials, and overhead without offsetting revenue. Free cash flow is also negative, as expected when a company is funding its pipeline. Capital spending on physical assets is minimal, so most cash usage is people, trials, and scientific work. The key question for the future is whether the existing cash runway, combined with potential future raises or partnerships, is enough to bridge the company to meaningful clinical and regulatory milestones.

Competitive Edge

Competitive Edge Competitively, Boundless Bio is trying to carve out a leadership role in a very specific, novel area of cancer biology: extrachromosomal DNA. This first-mover focus gives it a unique scientific identity, a specialized team, and a platform that could be hard for others to quickly replicate. However, the field is still emerging, and larger oncology players could eventually move into this space if the biology proves out. The company’s position is therefore promising but fragile: strong differentiation in concept and expertise, but unproven in the marketplace and still early in clinical validation, with execution on trials and partnerships likely to determine how defensible the position becomes.

Innovation and R&D

Innovation and R&D Innovation and R&D are clearly the core strengths of Boundless Bio. The Spyglass platform and the idea of ecDNA-directed therapies put the company at the frontier of precision oncology. The pipeline spans multiple approaches—from a DNA damage response inhibitor to a ribonucleotide reductase inhibitor and a prospective kinesin degrader—showing that the company is not betting everything on a single mechanism. At the same time, this is high scientific and clinical risk: tolerability challenges have already forced strategy adjustments, and upcoming trial readouts are critical proof points. Overall, R&D intensity and creativity are very high, but the outcome remains uncertain, as is typical for cutting-edge biotech.

Summary

Boundless Bio is an early-stage, high-science oncology company with no commercial products yet and a financial profile dominated by R&D spending and operating losses. Its balance sheet has improved recently, providing a better cash cushion but still leaving it reliant on external funding as it advances trials. Cash burn is steady, reflecting the cost of pursuing a differentiated but unproven ecDNA-focused strategy. On the strategic side, the company’s first-mover position in ecDNA biology, proprietary platform, and innovative pipeline create meaningful upside potential if clinical data are favorable. The flip side is high technical, clinical, and financing risk, with the company’s future depending heavily on upcoming trial outcomes and its ability to maintain funding through to later-stage development.

NEWS

November 24, 2025 · 7:00 AM UTC

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Read more

November 5, 2025 · 7:00 AM UTC

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Read more

October 13, 2025 · 4:05 PM UTC

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Read more

September 4, 2025 · 9:00 AM UTC

BLOOMINGDALE'S UNVEILS BOLD FALL 2025 CAMPAIGN: JUST IMAGINE

Read more